PMID- 32078680
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210925
IS  - 2473-9537 (Electronic)
IS  - 2473-9529 (Print)
IS  - 2473-9529 (Linking)
VI  - 4
IP  - 4
DP  - 2020 Feb 25
TI  - A 4-gene leukemic stem cell score can independently predict the prognosis of 
      myelodysplastic syndrome patients.
PG  - 644-654
LID - 10.1182/bloodadvances.2019001185 [doi]
AB  - Myelodysplastic syndrome (MDS) comprised a heterogeneous group of diseases. The 
      prognosis of patients varies even in the same risk groups. Searching for novel 
      prognostic markers is warranted. Leukemic stem cells (LSCs) are responsible for 
      chemoresistance and relapse in leukemia. Recently, expressions of 17 genes 
      related to stemness of LSCs were found to be associated with prognosis in acute 
      myeloid leukemia patients. However, the clinical impact of LSC genes expressions 
      in MDS, a disorder arising from hematopoietic stem cells, remains unclear. We 
      analyzed expression profile of the 17 stemness-related genes in primary MDS 
      patients and identified expression of 4 genes (LAPTM4B, NGFRAP1, EMP1, and CPXM1) 
      were significantly correlated with overall survival (OS). We constructed an LSC4 
      scoring system based on the weighted sums of the expression of 4 genes and 
      explored its clinical implications in MDS patients. Higher LSC4 scores were 
      associated with higher revised International Prognostic Scoring System (IPSS-R) 
      scores, complex cytogenetics, and mutations in RUNX1, ASXL1, and TP53. High-score 
      patients had significantly shorter OS and leukemia-free survival (LFS), which was 
      also confirmed in 2 independent validation cohorts. Subgroup analysis revealed 
      the prognostic significance of LSC4 scores for OS remained valid across IPSS-R 
      lower- and higher-risk groups. Furthermore, higher LSC4 score was an independent 
      adverse risk factor for OS and LFS in multivariate analysis. In summary, LSC4 
      score can independently predict prognosis in MDS patients irrespective of IPSS-R 
      risks and may be used to guide the treatment of MDS patients, especially 
      lower-risk group in whom usually only supportive treatment is given.
CI  - (c) 2020 by The American Society of Hematology.
FAU - Wang, Yu-Hung
AU  - Wang YH
AD  - Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan 
      University, Taipei, Taiwan; and.
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Lin, Chien-Chin
AU  - Lin CC
AD  - Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan 
      University, Taipei, Taiwan; and.
AD  - Division of Hematology, Department of Internal Medicine.
AD  - Department of Laboratory Medicine, and.
FAU - Yao, Chi-Yuan
AU  - Yao CY
AD  - Division of Hematology, Department of Internal Medicine.
AD  - Department of Laboratory Medicine, and.
FAU - Hsu, Chia-Lang
AU  - Hsu CL
AD  - Department of Medical Research, National Taiwan University Hospital, Taipei, 
      Taiwan.
FAU - Hou, Hsin-An
AU  - Hou HA
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Tsai, Cheng-Hong
AU  - Tsai CH
AD  - Division of Hematology, Department of Internal Medicine.
FAU - Chou, Wen-Chien
AU  - Chou WC
AD  - Division of Hematology, Department of Internal Medicine.
AD  - Department of Laboratory Medicine, and.
FAU - Tien, Hwei-Fang
AU  - Tien HF
AD  - Division of Hematology, Department of Internal Medicine.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood Adv
JT  - Blood advances
JID - 101698425
RN  - 0 (LAPTM4B protein, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (Oncogene Proteins)
SB  - IM
MH  - Humans
MH  - *Leukemia, Myeloid, Acute/diagnosis/genetics
MH  - Membrane Proteins
MH  - *Myelodysplastic Syndromes/diagnosis/genetics
MH  - Oncogene Proteins
MH  - Prognosis
MH  - Risk Factors
MH  - Stem Cells
PMC - PMC7042996
COIS- Conflict-of-interest disclosure: The authors declare no competing financial 
      interests.
EDAT- 2020/02/23 06:00
MHDA- 2021/05/15 06:00
PMCR- 2020/02/20
CRDT- 2020/02/21 06:00
PHST- 2019/11/04 00:00 [received]
PHST- 2020/01/24 00:00 [accepted]
PHST- 2020/02/21 06:00 [entrez]
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/02/20 00:00 [pmc-release]
AID - S2473-9529(20)31470-1 [pii]
AID - 2019/ADV2019001185 [pii]
AID - 10.1182/bloodadvances.2019001185 [doi]
PST - ppublish
SO  - Blood Adv. 2020 Feb 25;4(4):644-654. doi: 10.1182/bloodadvances.2019001185.